Indication
For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
Medicine details
- Medicine name:
- mirikizumab (Omvoh)
- SMC ID:
- SMC2822
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Publication due date:
- 11 August 2025